ClinicalTrials.gg
RecruitingNCT06962306OPAL-CleftUpdated Apr 14, 2026

Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery

A Phase 4 interventional study of Methadone hydrochloride and Fentanyl/Hydromorphone in Cleft Palate, Pain and Postoperative Care, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Duke University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Months to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Cleft Palate with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Cleft Palate · United States.

Planned enrollment
9th of 22
60 · median 47
Started
2025
with 2 others
Phase 4
2 of 31
1 open now
Primary completion
2027-06
later than 6 of 10 live
Registered
28th of 31
by date
Lead sponsor
2 of 31
Duke University

Among the 31 studies in Cleft Palate with a site in United States, this one is the 9th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 28th registered.

Cleft Palate

123 studies on the registry are indexed under Cleft Palate; 35 are open to participants now.

Browse Cleft Palate studies →

Open to participants now

9 of the 31 studies in Cleft Palate with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Cleft Palate studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 20 take children under 18; 2 take healthy volunteers.

This study: 6 Months to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Cleft Palate with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.

Read the detailed description

This is a single center, randomized, double blind, parallel-group dose escalation investigation in infants and children undergoing cleft palate surgery which will compare post operative pain control indices for patients receiving short acting versus long acting opioids as perioperative analgesics. Surgical and anesthesia care, except for opioid management, are not altered for study purposes. Subjects are randomized 2:1 to either long-duration (methadone) or short-duration opioid (fentanyl, hydromorphone) through the perioperative period. Exploratory data will be collected for up to 30 days post-operatively.

03

Conditions studied

  • Cleft Palate
  • Pain
  • Postoperative Care
  • Perioperative Care
  • Children

Keywords

  • Cleft palate surgery
  • Perioperative pain management
  • Analgesia
  • Methadone
04

Who can participate

Ages eligible
6 Months to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 months to 4 years of age
  • Primary cleft palate repair
  • Signed by parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • History of chronic kidney or liver disease
  • Planned admission to the Pediatric Intensive Care Unit (PICU)
  • Additional procedures under general anesthesia for which opioids would be prescribed
  • Any patient ineligible for study participation at the discretion of the investigators
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Methadone

    Methadone 0.2-0.25 mg/kg actual body weight

    Drug: Methadone hydrochloride

  • Active comparator
    Fentanyl/Hydromorphone

    Fentanyl/Hydromorphone per routine care

    Drug: Fentanyl/Hydromorphone

Interventions

06

What researchers measure

Primary outcomes

  1. Total amount of opioids medication administered

    Post-PACU in-hospital opioid use in oral morphine milligram equivalents (OMEs) per kilogram through POD1

    Time frame: From PACU discharge through postoperative day 1 (POD1)

Secondary outcomes

  1. Total amount of opioid medications administered

    Total (post-PACU in-hospital and post-discharge) opioids used (number of daily doses and OME/kg)

    Time frame: Up to 7 days after surgery

  2. Postanesthesia Care Unit (PACU) opioid medication administration

    Binary (yes/no) need for opioid administration in the PACU

    Time frame: Up to 6 hours after surgery

  3. Area under the curve (AUC) pain trajectories

    In-hospital AUC pain trajectories calculated from pain intensity scores on the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain.

    Time frame: Through hospital discharge (up to 4 days)

  4. Average daily pain intensity

    Average daily pain scores using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain.

    Time frame: Up to 7 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared at the discretion of the PI upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: IPD will be available 1 year after study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Jun 4, 2027
CompletionEst.
Jul 4, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06962306
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Jun 4, 2025
Primary completion
Jun 4, 2027 (estimated)
Completion
Jul 4, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Lisa M. Einhorn, M.D.
Contact
lisa.einhorn@duke.edu
919 970 2805
Lisa M. Einhorn, M.D.
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methadone · Fentanyl · Hydromorphone

Start the discussion